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INTRODUCTION
METHODS
▪ PCI is a standard strategy for patients needing immediate 
coronary reperfusion
▪ These procedures are performed by either radial or 
femoral access site
▪ Current guidelines recommend anticoagulant therapy 
including heparin or bivalirudin to reduce procedural 
complications such as thrombosis. 
▪ ACT is used to maintain the degree of anticoagulation 
during the procedure
▪ Bivalirudin was introduced as an alternative to heparin 
because of its anticoagulant efficacy and its ability to 
reduce bleeding in prospective clinical trials
▪ Bivalirudin maybe associated with increased thrombosis
▪ The HEAT-PPCI trial suggests bivalirudin maybe associated 
with more stent thrombosis, recurrent infarction events 
and no difference in bleeding in comparison to heparin
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▪ Compare the ACT of bivalirudin to heparin
▪ Identify incidence of catheter related thrombosis and 
bleeding
▪ Compare vascular complications rates with radial versus 
femoral artery approach
▪ Evaluate the cost associated with the use of heparin or 
bivalirudin
STUDY OBJECTIVES 
A comparison of heparin vs bivalirudin in patients undergoing percutaneous coronary intervention (PCI) in achieving 




▪ To evaluate and determine whether the use of 
bivalirudin will result in faster ACT compared to 
heparin in patients undergoing PCI
Secondary: 
▪ Bleeding defined by BARC 
▪ Use of dual antiplatelet therapy 
▪ Vascular complications and the duration 
associated with radial versus femoral artery 
approach
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This retrospective study will include patients undergoing PCI 
with either the use of heparin or bivalirudin at two St. Rose 
Dominican hospitals: St. Rose Siena and St. Rose San Martin. 
This data will be collected by reviewing the drug usage report 























15 ± 9.48 14 ± 10.23 0.41 
Discussion: 
▪ More patients reached therapeutic ACT with 
bivalirudin 
▪ No difference in time to reach therapeutic ACT
▪ No difference in secondary outcomes  
▪ Significantly higher cost with bivalirudin 
Limitations: 
▪ Therapeutic window of ACT is smaller with heparin 
▪ More patients with femoral artery approach
▪ More therapeutic ACT with bivalirudin compared to 
heparin during PCI 
▪ Higher cost with bivalirudin compared to heparin 
▪ No difference in bleeding
CONCLUSION
